南模生物(688265) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥87,214,843.35, representing a year-on-year increase of 2.08%[5] - The net profit attributable to shareholders for Q3 2023 was a loss of ¥11,708,046.36, with a year-to-date loss of ¥14,611,743.83[5] - The basic and diluted earnings per share for Q3 2023 were both -¥0.15, reflecting a decrease of 190% year-on-year[6] - The net profit for Q3 2023 was -14,611,743.83 RMB, compared to -75,071.53 RMB in Q3 2022, indicating a significant increase in losses year-over-year[26] - The total operating profit for Q3 2023 was -19,219,649.96 RMB, compared to -3,594,726.72 RMB in the same period last year, reflecting a worsening operational performance[25] - Basic and diluted earnings per share for Q3 2023 were both -0.19 RMB, compared to 0.00 RMB in Q3 2022, reflecting a negative performance[27] Research and Development - The total R&D expenditure for Q3 2023 was ¥19,080,238.20, accounting for 21.88% of revenue, a decrease of 3.34 percentage points compared to the previous year[6] - Research and development expenses continued to rise as the company increased investment in areas such as neurodegenerative diseases and autoimmune diseases[11] - Research and development expenses increased to 58,347,615.01 RMB in Q3 2023, up from 44,957,893.67 RMB in Q3 2022, showing a 29.7% increase[25] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was -¥23,998,804.39, indicating cash outflow[6] - The net cash flow from operating activities was -39.82 million, although there was an improvement in customer payment collection this year[12] - The total cash inflow from operating activities for the first three quarters of 2023 was 245,049,621.94 RMB, compared to 190,703,456.29 RMB in the same period of 2022, representing a 28.5% increase[28] - The net cash flow from operating activities for the first three quarters of 2023 was -23,998,804.39 RMB, worsening from -17,163,740.37 RMB in the first three quarters of 2022[28] - Cash and cash equivalents as of September 30, 2023, amounted to RMB 99,888,190.20, a decrease of 72.8% from RMB 368,032,631.50 at the end of 2022[18] - The company reported a decrease in cash and cash equivalents of $267.55 million for the quarter[29] Operating Costs and Expenses - The company experienced a significant increase in sales expenses due to efforts to expand both domestic and international markets, impacting overall profitability[10] - The total operating costs for the first three quarters of 2023 were RMB 295,805,196.53, up from RMB 234,245,219.39 in the previous year, reflecting a year-on-year increase of 26.3%[23] - The total sales expenses for Q3 2023 were 39,427,556.29 RMB, up from 20,953,540.37 RMB in Q3 2022, marking an increase of 88.2%[25] - The financial expenses for Q3 2023 were 1,366,051.33 RMB, compared to -3,739,571.40 RMB in Q3 2022, indicating a shift from income to expense[25] - The tax expenses for Q3 2023 were -4,644,898.12 RMB, compared to -3,662,757.43 RMB in Q3 2022, showing an increase in tax liabilities despite losses[25] Assets and Liabilities - The company's total assets at the end of Q3 2023 were ¥2,006,100,814.64, a decrease of 2.32% from the end of the previous year[6] - The company's total assets decreased to RMB 2,006,100,814.64 as of September 30, 2023, down from RMB 2,053,677,965.52 at the end of 2022, representing a decline of 2.3%[21] - The total liabilities as of September 30, 2023, were RMB 250,702,835.57, a decrease of 13.0% from RMB 287,751,134.70 at the end of 2022[21] - The company's equity attributable to shareholders was RMB 1,755,397,979.07, slightly down from RMB 1,765,926,830.82 at the end of 2022[21] Strategic Focus and Future Plans - The company plans to continue focusing on R&D and market expansion despite current financial challenges[10] - The company is actively expanding its domestic market share while also pursuing overseas market opportunities[11] - The company is focusing on expanding its market presence and enhancing product development strategies in the upcoming quarters[22] - The company has invested in new technologies and product lines to drive future growth and competitiveness[22] - The company plans to continue monitoring market trends and adjusting its strategies accordingly to optimize performance[22]